Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

I lighed med sidste år prøver vi igen at udvælge en lille håndfuld aktier blandt de børsnoterede life science aktier på ...

Også hos Jefferies har man for nyligt justeret sit kursmål, der nu lyder på 515 kr., hvilket indikerer et negativt potentiale ...

Presset på medicinalgiganten Novo Nordisk vokser, efter at 11 banker har skåret kursanbefalingen på selskabets aktier ned ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in cystic fibrosis, cancer and possibly chronic pain.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For ...